Thymosin Alpha-1

Thymosin Alpha-1 (Ta1) is a 28-amino acid peptide with the sequence Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn and a molecular weight of approximately 3,108 Da. The N-terminal serine is acetylated, a post-translational modification critical for biological activity. Ta1 is naturally produced by thymic epithelial cells and was first isolated and characterized by Allan Goldstein at the George Washington University in the 1970s from the thymic fraction known as Thymosin Fraction 5.

The thymus gland is the central organ of T-cell development and immune regulation. Beginning in puberty, the thymus undergoes progressive involution (shrinkage and fatty replacement), declining to approximately 15% of peak mass by age 50. This thymic involution directly reduces naive T-cell output and is a primary driver of immunosenescence. Ta1 supplementation compensates for declining endogenous production by directly promoting the differentiation of bone marrow progenitor cells into mature T-cells and enhancing the function of existing T-cell populations.

The mechanism of action involves activation of Toll-like receptors (TLR2, TLR9) on dendritic cells, leading to enhanced antigen presentation, increased MHC class I and II expression, and upregulation of co-stimulatory molecules (CD80, CD86). Ta1 also stimulates the maturation of CD4+ and CD8+ T-cells, promotes the generation of cytotoxic T-lymphocytes, and enhances natural killer (NK) cell cytotoxicity. Importantly, Ta1 modulates rather than simply stimulates the immune system: it increases suppressed immune function while downregulating excessive inflammatory responses by promoting regulatory T-cell (Treg) activity and normalizing the Th1/Th2 cytokine balance.

As a pharmaceutical product (Zadaxin, manufactured by SciClone Pharmaceuticals), Ta1 is approved in over 35 countries for treatment of hepatitis B (chronic), hepatitis C (as adjunct to interferon), and as an immune adjuvant in cancer immunotherapy. A meta-analysis of 8 randomized controlled trials (N=812) in chronic hepatitis B demonstrated significantly improved viral clearance rates compared to interferon alone (Journal of Viral Hepatitis, 2004). In oncology, Ta1 combined with chemotherapy improved 1-year survival rates in non-small cell lung cancer and hepatocellular carcinoma trials. Over 1 million patients have received Zadaxin clinically worldwide.

During the COVID-19 pandemic, multiple clinical studies investigated Ta1 as adjunct therapy for critically ill patients. A retrospective study by Liu et al. (N=76, published in Clinical Infectious Diseases, 2020) showed that Ta1 treatment was associated with a 60% reduction in 28-day mortality among severe COVID-19 patients. Ta1-treated patients showed restored CD4+ and CD8+ T-cell counts and reduced levels of inflammatory markers (IL-6, CRP). These findings are consistent with Ta1's dual role as an immune enhancer and anti-inflammatory modulator.

Ta1 is administered subcutaneously, with a plasma half-life of approximately 2 hours. Standard pharmaceutical dosing is 1.6 mg (Zadaxin formulation) administered twice weekly. Research protocols have studied doses ranging from 0.8-6.4 mg subcutaneously. Ta1 achieves peak plasma concentration within 1-2 hours post-injection, with biological effects on T-cell markers detectable for 3-7 days. The peptide does not require reconstitution in the Zadaxin formulation (pre-filled syringes), but lyophilized research-grade material should be reconstituted with sterile water or bacteriostatic water.

Lyophilized Ta1 should be stored at 2-8C (refrigerated) and is stable for 24+ months. Reconstituted solutions should be refrigerated and used within 14 days. The peptide is stable at pH 5.0-7.5. Given its 28-amino acid length, Ta1 is more sensitive to physical degradation (aggregation) than smaller peptides, so vigorous shaking should be avoided during reconstitution. Gentle swirling is recommended.

The safety profile of Ta1 is extensively documented across over 40 years of clinical use and more than 1 million treated patients. No serious adverse events have been attributed to Ta1 in clinical trials or post-marketing surveillance. Reported side effects are limited to occasional mild injection site reactions and transient low-grade fever (consistent with immune activation). No autoimmune exacerbation, hepatotoxicity, or hematological adverse effects have been observed. Ta1 is considered safe in immunocompromised populations, including HIV/AIDS patients and transplant recipients on immunosuppressive therapy.